Cover Image
市場調查報告書

全球遺傳性血管水腫市場 - 全球趨勢與預測

Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast till 2025

出版商 Coherent Market Insights 商品編碼 604422
出版日期 內容資訊 英文 175 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球遺傳性血管水腫市場 - 全球趨勢與預測 Hereditary Angioedema Market, by Drug Class, Route of Administration, Distribution Channel, and Region - Global Trends and Forecast till 2025
出版日期: 2018年02月10日 內容資訊: 英文 175 Pages
簡介

本報告提供全球遺傳性血管水腫市場相關調查,市場現狀與今後發展趨勢,各市場區隔趨勢,及主要加入企業的簡介等彙整資料。

第1章 與調查目的假設

第2章 市場概要

第3章 市場趨勢,法律規章,趨勢分析

  • 市場趨勢
  • 主要的焦點
  • 開發平台分析
  • 法律規章指南
  • 流行病學

第4章 各類藥物市場

  • 簡介
  • C1酯酶抑製劑
  • 激肽釋放酶抑製劑
  • Bradykinin受體
  • 弱毒化雄激素
  • 其他

第5章 各給藥途徑市場

  • 簡介
  • 皮下
  • 靜脈注射
  • 口服

第6章 各流通管道市場

  • 簡介
  • 院內藥局
  • 零售藥局
  • 電子商務

第7章 各地區市場

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第8章 競爭環境

  • 熱圖分析
  • 市場佔有率分析
  • 企業簡介
  • 分析師的見解

第9章 章節

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Hereditary angioedema (HAE) is characterized by acute skin and mucosal edema caused by an autosomal dominant mutation of the genes. The current treatments of the condition include the HAE drugs which can be administered intravenously, subcutaneously or taken orally. The disease causes swelling particularly of the face and airways and abdominal cramping. The World Allergy Organization (WAO) has set out guidelines to use the different class of drugs such as esterase inhibitors, kallikrein inhibitors and other drugs approved to treat hereditary angioedema.

Market Dynamics

The major factor driving growth of the hereditary angioedema market include intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary angioedema market growth.

Key features of the study:

This report provides in-depth analysis of hereditary angioedema market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global hereditary angioedema market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include CSL Behring, Shire Plc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Adverum Biotechnologies, Attune Pharmaceuticals and Pharming Healthcare, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology upgrade, market expansion, and marketing tactics

The global hereditary angioedema market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

  • Global Hereditary Angioedema Market, By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • Global Hereditary Angioedema Market, By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • Global Hereditary Angioedema Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • Global Hereditary Angioedema Market, By Geography:
  • North America
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Drug Class:
  • C1 Esterase Inhibitor
  • Kallikrein Inhibitor
  • Bradykinin Receptor
  • Attenuated Androgens
  • Others
  • By Route of Administration:
  • Subcutaneous
  • Intravenous
  • Oral
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • e-Commerce
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • CSL Behring*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Shire Plc.
  • Pharming Healthcare, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Attune Pharmaceuticals, Inc.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Key Highlights
  • Pipeline Analysis
  • Regulatory Guidelines
  • Epidemiology

4. Global Hereditary Angioedema Market, By Drug Class, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • C1 Esterase Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Kallikrein Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Bradykinin Receptor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Attenuated Androgens
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

5. Global Hereditary Angioedema Market, By Route of Administration, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

6. Global Hereditary Angioedema Market, By Distribution Channel, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, 2017 - 2025
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)
  • e-Commerce
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2025, (US$ Million)

7. Global Hereditary Angioedema Market, By Region, 2017 - 2025, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2016 and 2025 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2025
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2025, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2025, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
    • CSL Behring*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Shire Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Pharming Healthcare, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • BioCryst Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Ionis Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Attune Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Arrowhead Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Adverum Biotechnologies
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact

Browse 58 market data tables and 32 figures on "Hereditary Angioedema Market - Global forecast to 2025".

Back to Top